SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENT OF ENTHESITIS IN PATIENTS WITH ANKYLOSING SPONDYLITIS: POOLED ANALYSIS OF FOUR PIVOTAL PHASE 3 STUDIES
Schett G, Baraliakos X, Van Den Bosch F, Deodhar A, Gensler LS, Ostergaard M, Agawane S, Das Gupta A, Mpofu S, Fox T, Winseck A, Shete A, Porter B (2019)
Publication Type: Conference contribution
Publication year: 2019
Journal
Publisher: BMJ PUBLISHING GROUP
City/Town: LONDON
Pages Range: 873-874
Conference Proceedings Title: ANNALS OF THE RHEUMATIC DISEASES
Event location: Madrid
DOI: 10.1136/annrheumdis-2019-eular.695
Authors with CRIS profile
Involved external institutions
University of California San Francisco (UCSF)
United States (USA) (US)
Novartis AG
Switzerland (CH)
University of Copenhagen
Denmark (DK)
Oregon Health and Science University (OSHU)
United States (USA) (US)
University Hospital Ghent
Belgium (BE)
Rheumazentrum Ruhrgebiet
Germany (DE)
United States (USA) (US)
Novartis AG
Switzerland (CH)
University of Copenhagen
Denmark (DK)
Oregon Health and Science University (OSHU)
United States (USA) (US)
University Hospital Ghent
Belgium (BE)
Rheumazentrum Ruhrgebiet
Germany (DE)
How to cite
APA:
Schett, G., Baraliakos, X., Van Den Bosch, F., Deodhar, A., Gensler, L.S., Ostergaard, M.,... Porter, B. (2019). SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENT OF ENTHESITIS IN PATIENTS WITH ANKYLOSING SPONDYLITIS: POOLED ANALYSIS OF FOUR PIVOTAL PHASE 3 STUDIES. In ANNALS OF THE RHEUMATIC DISEASES (pp. 873-874). Madrid, ES: LONDON: BMJ PUBLISHING GROUP.
MLA:
Schett, Georg, et al. "SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENT OF ENTHESITIS IN PATIENTS WITH ANKYLOSING SPONDYLITIS: POOLED ANALYSIS OF FOUR PIVOTAL PHASE 3 STUDIES." Proceedings of the Annual European Congress of Rheumatology (EULAR), Madrid LONDON: BMJ PUBLISHING GROUP, 2019. 873-874.
BibTeX: Download